Search

This document is a reply from the authors of a systematic review and meta-analysis of randomized controlled trials on the effects of dapagliflozin and empagliflozin on 6-minute walk distance in heart failure patients. The authors address questions raised by other researchers regarding their study. They explain their rationale for excluding certain studies, clarify their statistical analysis methods, and discuss the inclusion of secondary outcomes in their analysis. They also acknowledge the need for further investigation and emphasize the limitations of their study. [Extracted from the article]